NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award

Publish Date:

Monday, February 2, 2015

Category:

Ebola Spotlight

News Organization:

NewLink Genetics

Source URL:

http://investors.linkp.com/releasedetail.cfm?ReleaseID=888640

NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.

Twitter

@lauriekay21 Thanks for sharing your story, Laurie! We wish your husband the best of luck in the future.-42 min 42 sec ago

Creating a healthy workplace for our employees is just as important to us as creating a healthier society:… https://t.co/sBgtU6I7lG-3 hours 11 min ago

Announcing the Alexa #DiabetesChallenge finalists! 5 voice-enabled solutions that can help improve patients’ lives: https://t.co/75PJMt6TrS-5 hours 9 min ago